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Polymorphisms in several distinct genomic regions, including the F7 gene, were recently associated with
factor VII (FVII) levels in European Americans (EAs). The genetic determinants of FVII in African Americans
(AAs) are unknown. We used a 50 000 single nucleotide polymorphism (SNP) gene-centric array having
dense coverage of over 2 000 candidate genes for cardiovascular disease (CVD) pathways in a community-
based sample of 16 324 EA and 3898 AA participants from the Candidate Gene Association Resource
(CARe) consortium. Our aim was the discovery of new genomic loci and more detailed characterization of
existing loci associated with FVII levels. In EAs, we identified three new loci associated with FVII, of which
APOA5 on chromosome 11q23 and HNF4A on chromosome 20q12–13 were replicated in a sample of 4289
participants from the Whitehall II study. We confirmed four previously reported FVII-associated loci
(GCKR, MS4A6A, F7 and PROCR) in CARe EA samples. In AAs, the F7 and PROCR regions were significantly
associated with FVII. Several of the FVII-associated regions are known to be associated with lipids and other
cardiovascular-related traits. At the F7 locus, there was evidence of at least five independently associated
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SNPs in EAs and three independent signals in AAs. Though the variance in FVII explained by the existing loci
is substantial (20% in EA and 10% in AA), larger sample sizes and investigation of lower frequency variants
may be required to identify additional FVII-associated loci in EAs and AAs and further clarify the relationship
between FVII and other CVD risk factors.
INTRODUCTION
Coagulation Factor VII (FVII) is a vitamin K-dependent serine
protease that is activated in response to vascular or tissue
injury. Activated FVII (FVIIa) interacts with tissue factor to
initiate coagulation (1). The association of FVII with cardio-
vascular disease (CVD) events is uncertain, with some positive
and negative findings (2–6). Commonly, FVII had an associ-
ation in unadjusted analyses, but this was often removed by
adjusting for known CVD risk factors, especially lipids. Poly-
morphisms in the FVII gene (F7) have been associated with
increased risk of coronary heart disease and stroke in some
studies but not all (7–10).
FVII levels are highly heritable (estimates range from 53 to
63%) and polymorphisms in F7 account for approximately a
third of the variance of FVII levels in European Americans
(EAs) (11–13). A recent genome-wide association study
(GWAS) in EAs confirmed that polymorphisms in the F7
gene region on chromosome 13q34 are strongly associated
with FVII levels and also identified novel associations in
four additional genomic regions: GCKR, ADH4, MS4A6A
and PROCR (14). Whether any of these or other genetic loci
are associated with FVII levels in African Americans (AAs)
is unknown.
The purpose of this study was to (i) perform more detailed
characterization of FVII-associated loci and fine-mapping of
previously discovered associations in EAs; and (ii) identify
genes associated with FVII levels in AAs. We analyzed
samples from a consortium of community-based prospective
cohort studies [the Candidate Gene Association Resource
(CARe)] with EA and AA participants genotyped using the
custom 50 K single nucleotide polymorphism (SNP) cardio-
vascular gene-centric ITMAT Broad-CARe (IBC) array. The
IBC array has dense coverage of over 2000 CVD candidate
genes and includes SNPs selected to ensure that common pat-
terns of genetic variation in populations of European and
African descent are well-captured.
RESULTS
Participant characteristics
The characteristics of our EA and AA study populations are
reported in Table 1. Prior to exclusion of individuals due to
low genotyping call rates, there were a total of 16 352 EAs
and 3948 AAs. The mean age at FVII measurement ranged
from 30 [Coronary Artery Risk in Young Adults (CARDIA)]
to 73 [Cardiovascular Health Study (CHS)] years. Mean FVII
levels were higher in the studies which sampled older individ-
uals. The prevalence of cardiovascular risk factors tended to
be higher among AAs than EAs. FVII levels did not consistently
differ by race, with higher levels found among AAs compared
with EAs in CHS and lower levels found among AAs compared
with EAs in CARDIA. After filtering individuals with less than
90% genotype call rate, our final meta-analysis sample sizes
were 16 324 EA and 3898 AA subjects.
FVII association results in EAs
In EAs, 7 discrete regions spanning 12 candidate genes on the
IBC array contained SNPs significantly associated with FVII
levels (Table 2). Four of the FVII association signals in EAs
correspond to loci previously reported in a GWAS of three
of the same cohorts (GCKR on chromosome 2p23,
MS4A2-MS4A6A on chromosome 11q12, F7–F10 on chromo-
some 13q34 and PROCR on chromosome 20q11.2) (14). The
addition of the CARDIA cohort to the three cohorts used in
Smith et al. [Atherosclerosis Risk in Communities (ARIC),
CHS and Framingham Heart Study (FHS)] strengthened
these associations. A fifth FVII-associated locus reported by
Smith et al., which spans two alcohol dehydrogenase (ADH)
genes, ADH4 and ADH5, was not represented on the IBC
array.
Three of the genomic regions significantly associated with
FVII in EAs have not previously been reported, including
eight SNPs in or near the ZNF259/BUD13/APOA5 region on
chromosome 11q23, one SNP upstream of MLXIPL on chromo-
some 7q11 and a non-synonymous SNP in HNF4A on chromo-
some 20q12. To further investigate the three newly associated
FVII loci, we examined the results in 4289 participants from
the Whitehall II study (Table 3). For the top SNP in the
ZNF259/BUD13/APOA5 region on chromosome 11q23
(rs2266788) and the HNF4A non-synonymous SNP
(rs1800961), the magnitudes and directions of association
were similar in the Whitehall II study, replicating the CARe
results. Upon meta-analysis of the CARe and the Whitehall II
results, both SNPs reached or closely approached the conven-
tional level of ‘genome-wide significance’ (, 5×1028). The
chromosome 7q11 SNP upstream of MLXIPL (rs7777102)
was not available in the Whitehall II data set, and therefore
could not be validated.
FVII association results in AAs
In AA participants, three distinct regions were associated with
FVII (Table 4). Two of these regions were concordantly
associated with FVII in EAs (F7-F10, PROCR), while one
region appeared to be specific to AAs (two SNPs at 10p15
near PRKCQ), although the direction of the association was
similar to what was observed in EAs. Of the five remaining
loci associated with FVII in EAs, GCKR, MS4A2 and
HNF4A showed a similar direction of association in AAs
(Table 5). In AAs, effect estimates were smaller and
P-values were larger for the top SNP associations noted in
EAs. There were substantial observed allele frequency
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differences between the two populations for several of the top
SNPs that would result in differences in statistical power to
detect an effect when present. Notably, the PRKCQ SNP
(rs602419) had a minor allele frequency of only 0.02 in
EAs, compared with 0.32 in AAs. In addition, observed
linkage disequilibrium (LD) patterns differed between EAs
and AAs in the region of F7 and F10 genes, as shown in Sup-
plementary Material, Figures S1 and S2, respectively, with the
extent of LD considerably lower among AAs.
To further investigate the F7, PROCR and newly associated
PRKCQ region in AA, we assessed the association of the top
SNPs in 918 AA participants from the Women’s Health
Initiative (WHI) (Table 6). The magnitude and direction of
associations for the top F7 and PROCR SNPs were similar
between WHI and CARe, replicating the CARe AA results.
While the novel PRKCQ SNP was not significantly associated
with FVII levels in the WHI sample, the direction of associ-
ation was the same.
Fine-mapping of FVII-associated loci in EAs and AAs
Regional LD association plots for array-wide significant loci in
EAs and AAs are shown in Supplementary Material, Figures
S3–12. Based on assessment of regional LD association pat-
terns and results from the conditional regression analyses,
there was little evidence supporting multiple independent
association signals within the PROCR, PRKCQ, HNF4A,
MS4A2, APOA5, MLXIPL regions, and moderate evidence for
the GCKR region. In contrast, there was evidence for more
than one independent association at an array-wide significant
level in the F7 gene region in both EAs and AAs (Supplementary
Material, Table S1).
The regional plots for F7 (Supplementary Material, Figures
S3 and S4) demonstrate multiple significant loci in the F7–
F10 region for EA and AA. Step-wise regression analyses
revealed five independent signals in EAs (rs561241, rs555212,
rs3093265, rs3211727, rs493833) and three independent
signals in AAs (rs561241, rs493833, rs3093230) (Table 7).
All signals identified were in the F7 gene, except for one in
the F10 gene in EAs. In EA, the minor allele of SNPs
rs555212 was associated with higher FVII levels, whereas the
minor alleles of SNPs rs561241, rs3093265, rs3211727 and
rs493833 were associated with lower FVII levels. Together,
these SNPs explained 18% of the variation of normalized
FVII levels in EAs and 9% of the variation in AAs.
Observed LD patterns differed between EAs and AAs in the
region of the F7 and F10 genes, as shown in Supplementary
Material, Figures S1 and S2, with the extent of LD consider-
ably lower among AAs. The lower extent of LD between
SNPs in the F7, along with the results of conditional associ-
ation analysis, could be used to fine-map the FVII association
signals in this region. For example, the most significant SNP
(rs561241) in EAs, located within the F7 promoter region, is
in strong LD (r2. 0.9) with several other SNPs that span
the entire F7 gene region, including rs1755685, rs6039,
rs7981123 and rs493833. In AAs, the same SNP rs561241
showed LD (r2. 0.6) with only one other SNP, rs1755685,
also in the promoter region. These findings suggest that the
main signal associated with lower FVII levels is localized to
the F7 promoter region. Similarly, the promoter SNP associ-
ated with higher FVII levels in EA (rs555212) is in strong
LD with at least two other SNPs (rs3093229 and rs3093230)
located in the promoter region (r2. 0.98). In AA, there is
less LD between rs555212, rs3093229 and rs3093230 (pair-
wise r2 ranging between 0.4 and 0.5). Of these three SNPs,
rs3093230 is most strongly associated with higher FVII in AA.
Haplotype-based analysis confirmed the individual F7 SNP
association results (Supplementary Material, Table S2). There
were three prominent F7 haplotypes in EAs. The haplotype
tagged by rs555212 was associated with higher FVII levels,
while the haplotype tagged by rs561241 was associated with
lower FVII levels. In AA, there was greater haplotype diver-
sity, with five haplotypes having frequencies of at least 5%.
There are two haplotypes tagged by the minor allele of
rs555212; only the haplotype that additionally contains the
rs3093230 minor allele is associated with higher FVII levels
in AA.
Total variance explained by known and novel loci
When SNPs representing the five independent signals for the
F7/F10 region, the two potentially independent signals from
the GKCR region and the other loci identified in Tables 2
and 3 were all included simultaneously in a linear regression
model for the ARIC study, they explained a total of 20.2%
of the variance in age- and sex-adjusted normalized FVII
Table 1. Characteristics of the 16352 EA and 3948 AA study participantsa
ARIC CARDIA CHS FHSb
AA EA AA EA AA EA EA
N 2768 9123 463 753 717 3873 2603
Female, % 63 54 60 53 63 56 55
Current smoker, % 29 24 33 23 16 11 18c
Diabetes, % 13 5 2 3 8 8 7
Age, years 53+6 54 + 6 30 + 4 31 + 3 73+ 6 73 + 6 54 + 10
Body mass index, kg/m2 29.6+ 6.1 26.9+ 4.8 28.2+ 6.8 25.2+ 5.0 28.5+ 5.6 26.4+ 4.5 27.4+ 4.9
Median Factor VII activity (%, IQR) 115 (97, 133) 116 (100, 135) 85 (70, 99) 81 (68, 96) 110 (95, 127) 122 (106, 142) 99 (89, 110)d
aMean + SD for continuous variables, % for categorical variables. Only includes individuals with both FVII and IBC data.
bOffspring cohort at visit 5.
cSmoked in last year (other cohorts have a variable ‘current smoker’. This was not available for visit 5 in FHS).
dFVII antigen activity.
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levels in EAs, and 10.2% in AAs (adjusted R2 ¼ 0.202 and
0.102, respectively). Most of this variance is due to variation
in the F7 gene, with the five independent regions in the F7
gene explaining 18% of the variance, and the remaining loci
from Table 2 explaining the remaining 2% in ARIC EAs.
Comparison of genetic association results for FVII activity
versus FVII antigen assays
For each genomic region, associations of the top SNPs with
FVII antigen levels closely mirrored those with FVII activity
levels. Effect estimates and standard errors were similar, vali-
dating previous studies that have meta-analyzed activity and
antigen levels (Supplementary Material, Table S3).
DISCUSSION
By using a custom 50 K SNP genotyping array with dense,
multi-population tag SNP coverage of .2 000 genes in
CVD-related pathways including coagulation, we further
characterized regions of the genome associated with FVII
levels in EAs and AAs. Our findings can be summarized as
follows: (i) the chromosome 13q34 F7–F10 gene region con-
tained multiple variants associated with higher and lower FVII
in both EAs and AAs. (ii) The lower extent of LD among AA
enabled finer localization of the strongest F7 signals. (iii) We
identified two novel genomic regions significantly associated
with FVII in EAs, the ZNF259–BUD13–APOA5 gene
region on chromosome 11q23 and chromosome 20q12
HNF4A gene (4). Of other candidate regions associated with
FVII in EAs, we found evidence for replication of the chromo-
some 20 PROCR SNP rs867186 (Ser219Gly) and GCKR
associations with higher FVII levels in AAs; on the other
hand, FVII association with polymorphisms within the
MS4A2, APOA5 and HNF4A gene regions were not evident
in AAs.
Polymorphisms in the F7 gene could be grouped in into
three major haplotypes in European descent populations (5).
Compared with the most common or ‘wild-type’ haplotype,
the haplotype tagged by the minor allele of rs555212 (and
rs3093230) was associated with higher FVII levels while the
haplotype tagged by the minor allele at rs561241 was associ-
ated with lower levels. These results confirm previous findings
from smaller European population studies that SNPs tagging
these haplotypes constitute the major determinants of FVII
activity in EAs (5,15). Because of the large sample size of
CARe and the dense SNP coverage of the IBC genotyping
array, we were able to identify at least three additional variants
within the F7–F10 genes independently associated FVII
levels. Two of these are located within intron 5 of the F7
gene (rs493833 and rs3093265) and one within intron 1 of
the F10 gene (rs3093268).The strong LD among the promoter
variants in Europeans has previously hampered detailed
characterization of the functional variants responsible for
reduced FVII levels. Functional analysis of the F7 promoter
suggested that the 2323ins10 and 2122C (rs561241) variants
are strongly associated with decreased promoter activity. It has
remained uncertain whether the 2402A variant (rs510317) or
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promoter activity (16). In our analysis, AA showed greater F7
haplotype diversity, which suggested further localization of
the higher-expression F7 promoter region to rs3093230 (or
an untyped variant in LD).
Characterization of common cis-acting F7 gene variants
may have relevance for athero-thrombotic disease risk. The
F7 polymorphisms associated with higher FVII levels have
been associated with increased risk of stroke and myocardial
infarction (MI) in young women (5,17,18).The relationship
of haplotype C FVII-lowering polymorphisms to risk of clini-
cal CVD has been equivocal, with published meta-analyses of
MI (10) and stroke (19) showing no significant association.
Since our results suggest independent associations of several
additional F7 polymorphisms on FVII level, evaluation of
these variants in the context of clinical CVD risk, or extent
of subclinical atherosclerosis in young adults (20) both in
EA and AA populations, may be warranted.
Polymorphisms in LD with the PROCR Ser219Gly variant
(rs867186) have been strongly associated with higher soluble
endothelial protein C receptor (EPCR) levels, as well as
with higher levels of clotting FVII, FVIIa, protein C antigen
and several downstream markers of activated coagulation in
the extrinsic pathway (21–22) in whites. Binding of FVII/
FVIIa to soluble and/or membrane-associated EPCR and sub-
sequent endocytosis of the receptor-ligand complexes may be
important for regulating the circulating concentrations of FVII
and protein C (23). These findings have potential implications
for the role of the PROCR Ser219Gly dimorphism in risk of
clinical thrombotic disease (24,25).
FVII levels are correlated with other CVD risk factors, such
as lipid levels, body mass index and insulin resistance (6,26).
The causal nature and mechanisms of these associations
remain to be elucidated. There is a fairly well-described con-
nection between high-fat diet, triglycerides and FVII activity.
FVII and other vitamin K-dependent coagulation proteins bind
to triglyceride-rich lipid particles (27). Moreover, expression
of the F7 gene can be modulated by glucose and insulin
levels due to a specific promoter element (28). The association
of FVII levels with polymorphisms of the GCKR, APOA5,
MLXIPL and HNF4A genes suggests an additional level of
shared genetic regulation between FVII synthesis, glucose
metabolism and low-grade inflammation. The APOA5 SNP
rs6589566 that was discovered in our study was also associ-
ated with low density lipoprotein levels in a recent genome-
wide association scan (29). Other SNPs in LD with
rs6589566 (e.g. rs964184, rs1558861, rs4938303,
rs12280753) have been associated with high density lipopro-
tein (HDL-C) levels and triglyceride levels (30–34).
While the same SNPs were not identified in this study, var-
iants in or near PRKCQ have been found to be associated at a
genome-wide significance level with type I diabetes (35–36)
and rheumatoid arthritis (37–38). One non-synonymous SNP
in MXLIPL was also significantly associated with plasma tri-
glycerides in another recent genome-wide scan (33), although
LD information was not available between our SNP
(rs7777102) and theirs (rs3812316).
The GCKR gene product inhibits glucokinase in liver and
pancreatic islet cells and is considered a susceptibility gene
candidate for a form of maturity-onset diabetes of the
young. Polymorphisms of GCKR have been associated with
a number of metabolic and CVD traits, including HDL, trigly-
cerides, glucose, insulin resistance, renal function, C-reactive
protein and protein C levels. GWASs have shown that the
GCKR SNP identified in our study, rs1260326, is also associ-
ated with triglyceride levels (32), chronic kidney disease (39)
and 2 h post-load glucose levels (40).
This study has several notable strengths, including a large
sample size for both EA and AA participants. The IBC
custom chip enables a more comprehensive study of lower fre-
quency variants in comparison to GWAS. When comparing
findings between populations, it is important to note differ-
ences in findings for individual loci may be due to different
LD patterns, lower statistical power in AAs due to a smaller
sample size, difference in minor allele frequency or effect
modification by genetic or environmental factors.
In summary, we have confirmed and refined known loci, and
identified several new genomic loci associated with FVII levels,
including APOA5 and HNF4A in EAs. The chromosome 13q34
F7–F10 gene region contains multiple variants independently
associated with higher and lower FVII in both EAs and AAs.
Of other candidate regions associated with FVII in EA, we
found evidence for replication of the chromosome 20 PROCR
gene Ser219Gly and GCKR associations with higher FVII
levels in AAs; on the other hand, FVII association with poly-
morphisms within the MS4A2, APOA5 and HNF4A gene
regions were not evident in AAs. Larger samples and investi-
gation of lower frequency variants may be required to identify
additional FVII-associated loci in AAs.
Table 3. Replication of novel FVII-associated loci in EAs in the Whitehall II Study


















116165896 A 20.12 (0.02) 3.6 × 1027 22.6 (0.9) 0.0039 4.0 × 1029 Definite
7q MLXIPL, VPS37D rs7777102 72695953 A 0.08 (0.02) 1.24 × 1026 n/ad n/a n/a n/a
20q12–13 HNF4A rs1800961 42475778 T 20.17 (0.03) 1.5 × 1027 23.3 (1.4) 0.017 8.8 × 1028 Definite
WhII, Whitehall II Study.
aThe Whitehall II study utilized a different transformation for FVII levels. The direction of effect and the P-values were used to determine whether an association
replicated.
bMeta-analysis P-values were calculated using P-values and sample sizes, taking into account the direction of effect.
cProxy for rs6589566; R2¼ 0.92, D′ ¼ 1.0 in HapMap CEU.
dNot available in the Whitehall II study; no proxy was available.
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MATERIALS AND METHODS
CARe discovery population
The purpose of the CARe (Candidate Gene Association
Resource) consortium is to bring together deeply phenotyped
prospective cohort studies to increase power for genetic
association scans of CVD and other disorders (41). Cohorts
included in this analysis of FVII levels are ARIC, CARDIA,
the CHS and the FHS. Further details of the participating
CARe studies are reported in the Supplementary Materials.
To be included in the current analysis, the participant must
have provided informed consent for genetic testing and had
FVII antigen levels or activity levels measured. Exclusion cri-
teria included use of the anticoagulant warfarin. In ARIC,
CHS and CARDIA (year 7 exam), FVII activity levels were
measured in citrated plasma by assaying clotting time using
FVII-deficient plasma (see (14), for ARIC and CHS; see
(42) for CARDIA). In FHS and CARDIA (year 20 exam),
FVII antigen levels were measured in ethylenediaminetetraa-
cetic acid plasma by Enzyme-linked immunosorbent assay
(Diagnostica Stago) (14,20). As CARe study participants
were examined at multiple time points, covariate values that
were included in the analyses were selected from the visit
closest to the time of FVII measurement. After excluding
study participants based on low genotyping quality control
(see further information below), there were a total of 16 352
EA and 3948 AA CARe study participants available for the
analysis.
Genotyping
Both AAs and EAs in CARe were genotyped using the 50 000
SNP, cardiovascular gene-centric IBC SNP array, described by
Keating et al. (43). The IBC SNP array includes 49 320 SNPs
selected across 2100 candidate loci for CVD. Of the five
genomic regions previously reported to be associated with
FVII in the Cohorts for Heart and Aging Research in
Genomic Epidemiology (CHARGE) consortium (GCKR,
ADH4, MS4A6A, F7 and PROCR), all except ADH4 are rep-
resented on the IBC array. Genotyping was done at the
Broad Institute (Cambridge, MA, USA). Criteria for DNA
sample exclusion based on genotype data included sex mis-
match, discordance among duplicate samples or sample call
rate ,95%. For each set of duplicates or monozygotic
twins, data from the sample with the highest genotyping call
rate were retained. SNPs were excluded when monomorphic,
the call rate was ,95% or Hardy–Weinberg equilibrium
(HWE) was P , 1025 in EAs. Given the genetic admixture
in AAs, there was no HWE filter used for AAs. After these
exclusions were applied, data remained on 47 539 working
SNPs.
Additional SNPs were imputed from HapMap Phases 1 and
2 using MACH (44–45), as described in detail under Sup-
plemental Materials. The total number of SNPs was
250 000 after adding the imputed SNPs. We reported the
genotyped results from the raw genotype data when a SNP
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Data analysis
Initial IBC-array-wide association analyses were conducted at
the Broad Institute, and subsequent analyses were conducted
at UNC-Chapel Hill. Family structure (where applicable)
was taken into account during the association analysis, using
a linear mixed-effects model (46). To generate a normally dis-
tributed outcome variable for use in association analyses, we
stratified the data by sex, race and cohort, and modeled FVII
levels as a function of age and study site (where applicable).
We inverse normally transformed the residuals, and recom-
bined the data from race and sex strata within each cohort
before conducting the association analyses. For both geno-
typed and imputed SNPs, we assumed an additive genetic
model. Consistent with this assumption, we used dosage
values (i.e. a value between 0.0 and 2.0 calculated as the
expected number of copies of the reference allele based on
the posterior probability of each of the three possible geno-
types) in the regression model implemented in PLINK (for
cohorts with unrelated individuals) or the linear mixed-effects
model implemented in genome-wide association study in
families (for cohorts with related individuals) (46,47). To
control for potential population stratification, we included
the top 10 principal components, calculated in Eigenstrat, as
covariates in the association analysis (48). Principal com-
ponents were calculated using the cleaned CARe IBC geno-
type data and the HapMap populations (CEU, YRI, CHB +
JPT) as reference (seed) populations.
After obtaining cohort- and race-specific results, we used
the METAL software to meta-analyze the data within race
(49). We used a fixed-effect Z-score approach when combin-
ing results from studies that analyzed FVII activity and
antigen levels. Meta-analyses were based on P-values and
weighted by sample sizes. We also calculated summary
effect estimates and standard errors by meta-analyzing the
three studies which measured FVII activity levels. As a sup-
plementary analysis, we compared effect estimates based on
FVII activity versus FVII antigen levels.
For the IBC array, the effective number of independent tests
was calculated to be 26 482 for AA and 20 544 for EA, based
on LD between markers on the array (50). To maintain an
overall type 1 error rate of 5%, a statistical threshold of a ¼
2 × 1026 (0.05/25000) was thus used to declare array-wide
(experiment-wide) significance.
Table 5. Comparison of top SNPs from Tables 2 and 3 in EAs and AAs
Region (Chr) Index SNP N (EA) MAFa
(EA)




P-value (AA) Genes in region
SNP identified in both EAs and AAs
13q34 rs561241 16324 0.12 0.88 (0.01) 6.78 × 102485 3855 0.13 0.57 (0.03) 1.02 × 10264 F7, F10
SNPs identified in EAs
20q11 rs11167260c
(rs867186)
16324 0.10 20.26 (0.02) 2.16 × 10238 3898 0.08 0.22 (0.05) 3.07 × 1026 PROCR
2p23 rs1260326 13691 0.42 0.09 (0.01) 1.55 × 10211 3880 0.15 0.04 (0.05) 0.460 GCKR
11q12 rs17529983 16324 0.42 20.12 (0.02) 2.82 × 1027 3898 0.09 0.05 (0.10) 0.558 MS4A2
11q23 rs6589566 16324 0.07 0.08 (0.02) 1.24 × 1026 3898 0.01 n/a n/a ZNF259, BUD13,
APOA5
7q rs7777102d 16324 0.17 20.17 (0.03) 1.62 × 1026 n/a n/a 20.13(0.16) 0.390 MLXIPL, VPS37D
20q12–13 rs1800961 13702 0.03 20.26 (0.02) 2.16 × 10238 3898 0.006 0.22 (0.05) 3.07 × 1026 HNF4A
SNPs identified in AAs
10p15 rs602419 13706 0.02 20.04 (0.05) 0.387 3898 0.32 20.13 (0.03) 3.60 × 1027 PRKCQ
20q11 rs7265317 15826 0.10 20.26 (0.02) 3.94 × 10237 3877 0.08 20.21 (0.04) 7.29 × 1027 PROCR
aMinor allele frequency.
bOrder is ARIC, CARDIA, CHS, FHS for EAs, and ARIC, CARDIA and CHS for AAs.
cProxy for rs867186 (R2¼ 1.0, D′ ¼ 1.0 in ARIC EAs) used here because rs867186 was only available in CARDIA and CHS for AAs.
dNo information for rs7777102 in AAs, and no proxies were available.
Table 6. Replication of array-wide significant regions identified in AAs in WHI-SHARe AAs (N ¼ 918)


















13q34 F7, rs561241 0.57 (0.03) 0.76 (0.08) ,1 × 10210 70 7.1 × 1024 ,1 × 10210 Definite
10p15 PRKCQ, rs602419 20.13 (0.03) 20.04 (0.05) 0.40 143 3.5 × 1024 0.0095, rs944715 Weakb
20q11 PROCR, rs867186c 20.20 (0.04) 20.36 (0.08) 9.7 × 1026 4 1.3 × 1022 9.7 × 10– 6,
rs867186
Definite
aGene region defined by the start of the first gene (in a multiple gene region) to the last position of the last gene as defined by the USC human genome browser,
build hg18.
bCriterion for ‘weak’: same direction of effect for index SNP.
crs7265317 was not available in the WHI data set.
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Haplotype analysis was conducted using the R-based soft-
ware package HAPLO.STATS for the known haplotypes in
the F7 gene represented by four SNPs (rs561241, rs2274030,
rs3093265 and rs6046) that tag common patterns of LD in
Caucasians (5), and an additional SNP that defined another
haplotype in AAs in our data (rs3093230). The association
of each haplotype with FVII levels, relative to the most
common referent haplotype, was estimated using generalized
linear models (haplo.glm). The EA and AA samples had the
same referent haplotype. Haplotype analyses were restricted
to the ARIC study (the largest sample) in EAs and AAs.
Conditional analyses
For genomic regions which initially revealed more than one
significant SNP in the association scan, we conducted con-
ditional regression analyses to estimate the number of inde-
pendently associated SNPs. Conditional analyses were
performed iteratively in a forward stepwise manner, with a
meta-analysis done at each stage. We began by conditioning
on the most significant SNP in the region (or a closely
linked proxy) by including it as a covariate in the linear
regression model, in each population. We determined
whether any other SNPs in that region remained significant
(defined as P , 2 × 1026) after meta-analysis. If some
results were still significant, we took the most significant of
those SNPs, and in the next round, conditioned on the top
SNPs from both rounds. This continued until there were no
longer any additional significant SNPs. To estimate the cumu-
lative proportion of variance in the sex- and age-adjusted, nor-
malized FVII levels explained by the associated SNPs, we
obtained the sum of the partial R2 for each of the associated
SNPs when all were simultaneously included in the regression
model, adjusting for 10 PCs. All conditional analyses were
conducted in SAS v. 9.2 (Cary, NC, USA).
EA replication cohort: Whitehall II Study
Replication analyses of novel FVII association findings for
EAs were performed in the Whitehall II study. Details of
this cohort study are provided in ref. (51). Briefly, 10 308
UK participants (70% men) were recruited between 1985
and 1988 of whom .6156 participants had blood samples
for DNA collected in 2002–2004. After filtering based on
call rates and removal of ancestry outliers based on principal
component analysis, custom genotyping for the IBC array
(48 032 SNPs) was available on 4289 individual of white
ancestry. Fasting blood samples were measured for FVII
activity in 1991–1993 by the method of Brozovic et al.
(52). Data analysis of inverse normalized FVII activity
levels was performed similarly to CARe using PLINK.
AA replication cohort: WHI
For replication of association findings in AAs, we used geno-
typed and imputed SNPs available through a GWAS per-
formed in the AA participants from the WHI. Of the 8421
AA women in the WHI-SHARe project who were genotyped
using the Affymetrix 6.0 chip, 984 of these women also had
FVII antigen and activity levels measured. Following the
primary data analysis plan, FVII association analyses were
performed, using PLINK for genotyped SNPs, and ProbAbel
for imputed SNPs (53).
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